autologous PD1-knockout CD19-specific CAR T cells BRL-201

{
  "id": "MLC-T-ONC-011744",
  "term": "autologous PD1-knockout CD19-specific CAR T cells BRL-201",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are non-virally gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to integrate a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 in the locus of the programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1) gene, with potential immunomodulating and antineoplastic activities. Upon administration, autologous PD1-knockout CD19-specific CAR T cells BRL-201 specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. Expression of PD-1, an inhibitory receptor expressed on activated T cells, plays a key role in cytotoxic T-lymphocyte (CTL) suppression, T-cell exhaustion and CTL apoptosis. PD-1 knockout may abrogate T-cell exhaustion and increase T-cell activity and cytotoxicity.",
  "synonyms": [
    "autologous CD19-targeted PD1 site-specific integrated CAR-T cells BRL-201",
    "autologous PD1-knockout anti-CD19-CAR T cells BRL-201"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-pd1-knockout-cd19-specific-car-t-cells-brl-201/"
}